Genentech vet sets up deal-making shop

20-year Genentech veteran Suzy Jones has left the biotech giant to set up her own shop helping small biotechs negotiate drug deals with the big boys in the biopharma industry. Jones says that DNA Ink already has two clients on board and is close to signing deals with more. There's so much good science out there and there are buyers," Jones told the San Francisco Business Times. "We'll do great deals and we'll do them quickly." Story

Suggested Articles

The series B positions ex-AveXis executives to build a biotech with a broad gene therapy pipeline and infrastructure to match.

Zydus Cadila has completed a phase 1 clinical trial of its COVID-19 vaccine ZyCoV-D, setting it up to move straight into a 1,000-subject phase 2 .

OrbiMed, Novartis Venture Fund and RA Capital Management have joined forces to fund and help launch GentiBio.